(Q28245467)

https://api.crossref.org/works/10.1517/13543780902980171

The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543780902980171

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543780902980171

Sorafenib in advanced clear-cell renal-cell carcinoma

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543780902980171

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543780902980171

Sorafenib in advanced hepatocellular carcinoma

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543780902980171

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543780902980171

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543780902980171

Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543780902980171

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543780902980171

ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the [...]

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543780902980171

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543780902980171

Integrative nonpharmacologic behavioral interventions for the management of cancer-related fatigue

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543780902980171

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

A small molecule-kinase interaction map for clinical kinase inhibitors

21 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Sunitinib: from rational design to clinical efficacy

21 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Pharmacokinetics of sunitinib in hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Attenuation of proteasome-induced proteolysis in skeletal muscle by {beta}-hydroxy-{beta}-methylbutyrate in cancer-induced muscle loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Immunotherapy for renal cell cancer in the era of targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Sunitinib in the management of gastrointestinal stromal tumours (GISTs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

PDGFRA activating mutations in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Activity of sunitinib in patients with advanced neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Treatment considerations for gallbladder cancer should include extent of surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Documentation of thyroid function in clinical studies with sunitinib: why does it matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Patient with malignant paraganglioma responding to the multikinase inhibitor sunitinib malate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Sequential therapy with sorafenib and sunitinib in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Breast cancer survivors and hot flashes: the search for nonhormonal treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Cutaneous side-effects of kinase inhibitors and blocking antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

Gestational Choriocarcinoma Mimicking a Uterine Adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780902980171

10.1517/13543780902980171

21 January 2018

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

4225900

4225900

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference